Literature DB >> 18996047

Alterations in circulating activin A, GDF-15, TGF-beta3 and MMP-2, -3, and -9 during one year of left ventricular reverse remodelling in patients operated for severe aortic stenosis.

Johannes L Bjørnstad1, Nils O Neverdal, Oystein A Vengen, Cathrine Wold Knudsen, Trygve Husebye, John Pepper, Mons Lie, Geir Christensen, Theis Tønnessen.   

Abstract

BACKGROUND: Patients with aortic stenosis (AS) develop left ventricular remodelling with cardiomyocyte hypertrophy and increased fibrosis. Following aortic valve replacement (AVR) reverse remodelling usually takes place. AIMS: To examine circulating levels of members of the transforming growth factor (TGF) beta superfamily and matrix metalloproteinases (MMP), known to have important effects on hypertrophy and extracellular matrix, in patients operated for AS.
METHODS: Circulating levels of activin A, GDF-15, TGF-beta3, MMP-2, -3, and -9 were measured in twenty-two patients undergoing AVR preoperatively, and 2 days, six months and 12 months postoperatively. Echocardiography and a six minute walking test evaluated reverse remodelling and physical performance.
RESULTS: Activin A increased at six (1081.00+/-98.05 pg/ml, p<0.05) and twelve months (1263.09+/-141.43 pg/ml, p<0.05) compared to the preoperative value (855.00+/-76.30 pg/ml) and correlated negatively to physical performance. The preoperative value was also increased compared to controls (639.54+/-63.05 pg/ml, p<0.05). GDF-15, MMP-3 and -9 were all increased at two days postoperatively (p<0.05). MMP-3 correlated with left ventricular end diastolic dimension (p<0.05). MMP-2 did not change during the study period. TGF-beta3 was only slightly reduced at six months postoperatively.
CONCLUSION: The observed alteration in circulating levels of members of the TGF-beta superfamily and MMPs might play a role in the reverse remodelling process following AVR for AS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18996047     DOI: 10.1016/j.ejheart.2008.09.010

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  11 in total

1.  Activin A Predicts Left Ventricular Remodeling and Mortality in Patients with ST-Elevation Myocardial Infarction.

Authors:  Jeng-Feng Lin; Shun-Yi Hsu; Ming-Sheng Teng; Semon Wu; Chien-An Hsieh; Shih-Jung Jang; Chih-Jen Liu; Hsuan-Li Huang; Yu-Lin Ko
Journal:  Acta Cardiol Sin       Date:  2016-07       Impact factor: 2.672

Review 2.  Targeting the myostatin signaling pathway to treat muscle wasting diseases.

Authors:  H Q Han; William E Mitch
Journal:  Curr Opin Support Palliat Care       Date:  2011-12       Impact factor: 2.302

3.  Growth differentiation factor (GDF)-15 blocks norepinephrine-induced myocardial hypertrophy via a novel pathway involving inhibition of epidermal growth factor receptor transactivation.

Authors:  Xin-ye Xu; Ying Nie; Fang-fang Wang; Yan Bai; Zhi-zhen Lv; You-yi Zhang; Zi-jian Li; Wei Gao
Journal:  J Biol Chem       Date:  2014-02-19       Impact factor: 5.157

4.  Correlation between growth differentiation factor-15 and collagen metabolism indicators in patients with myocardial infarction and heart failure.

Authors:  Fang-Fang Wang; Bao-Xia Chen; Hai-Yi Yu; Lin Mi; Zi-Jian Li; Wei Gao
Journal:  J Geriatr Cardiol       Date:  2016-01       Impact factor: 3.327

5.  Impact of the left ventricular mass index on the outcomes of severe aortic stenosis.

Authors:  Eri Minamino-Muta; Takao Kato; Takeshi Morimoto; Tomohiko Taniguchi; Moriaki Inoko; Tetsuya Haruna; Toshiaki Izumi; Shoichi Miyamoto; Eisaku Nakane; Kenichi Sasaki; Moritoshi Funasako; Koji Ueyama; Shinichi Shirai; Takeshi Kitai; Chisato Izumi; Kazuya Nagao; Tsukasa Inada; Eiji Tada; Akihiro Komasa; Katsuhisa Ishii; Naritatsu Saito; Ryuzo Sakata; Kenji Minatoya; Takeshi Kimura
Journal:  Heart       Date:  2017-07-06       Impact factor: 5.994

6.  Pharmacological Mechanisms of Tinglizi against Chronic Heart Failure Determined by Network Pharmacology and Molecular Docking.

Authors:  Liangtao Luo; Haowen Wang; Guowei Huang; Lu Zhang; Xiuwei Li; Chongyang Ma; Xing Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-06       Impact factor: 2.629

Review 7.  New insights into fibrosis from the ECM degradation perspective: the macrophage-MMP-ECM interaction.

Authors:  Xiangyu Zhao; Jiayin Chen; Hongxiang Sun; Yao Zhang; Duowu Zou
Journal:  Cell Biosci       Date:  2022-07-27       Impact factor: 9.584

8.  Secreted Wnt modulators in symptomatic aortic stenosis.

Authors:  Erik Tandberg Askevold; Lars Gullestad; Svend Aakhus; Trine Ranheim; Theis Tønnessen; Ole G Solberg; Pål Aukrust; Thor Ueland
Journal:  J Am Heart Assoc       Date:  2012-12-19       Impact factor: 5.501

9.  Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.

Authors:  Marc Iglarz; Kyle Landskroner; Yasmina Bauer; Magali Vercauteren; Markus Rey; Berengère Renault; Rolf Studer; Enrico Vezzali; Diego Freti; Hakim Hadana; Manuela Schläpfer; Christophe Cattaneo; Céline Bortolamiol; Edgar Weber; Brian R Whitby; Stéphane Delahaye; Daniel Wanner; Pauline Steiner; Oliver Nayler; Patrick Hess; Martine Clozel
Journal:  J Cardiovasc Pharmacol       Date:  2015-11       Impact factor: 3.105

Review 10.  Molecular biomarkers in cardiac hypertrophy.

Authors:  Liu Zhu; Chao Li; Qiang Liu; Weiting Xu; Xiang Zhou
Journal:  J Cell Mol Med       Date:  2019-01-16       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.